Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
China Resources Pharmaceutical Group Limited has called its first extraordinary general meeting of 2026 for 6 February in Beijing, where shareholders will vote on approving a new Sales Framework Agreement for 2026–2028, including the associated transaction caps and authorization for directors to execute related documents. The meeting will also consider a special resolution to adopt a new Articles of Association to replace the existing constitution, signaling a potential update to the company’s corporate governance framework, and the outcomes—decided by poll—may shape its operational arrangements and internal rules going forward.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated company listed on the Stock Exchange of Hong Kong, operating in the pharmaceutical industry. The group focuses on the production, distribution and sale of pharmaceutical products and related healthcare services in mainland China, leveraging a broad network and scale within the domestic healthcare market.
YTD Price Performance: 2.02%
Average Trading Volume: 12,761,952
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.52B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.